The company’s announcement reassured investors in the wake of last month’s news that the Alzheimer’s drug solanezumab had failed to demonstrate effectiveness during a large-scale clinical trial.
The point of chemo is to cure me. But these are not gentle chemicals. They sweep through my body like a tornado, with side effects that range from annoying to horrendous. But I have no choice.
Eli Lilly and Co. will bypass insurance companies to offer a discount on its best-selling insulin products for patients who lack health coverage or have high deductibles that require them to pay the full cost of some medications.
U.S. District Judge Amy Berman Jackson in Washington, D.C., will issue a decision on whether the combination of the companies risks higher costs for large employers around the country and should be blocked.
The gift is the largest to the IU School of Medicine by an alumnus. The medical school will use the money to establish the Brown Center for Immunotherapy to fight some of the world’s toughest diseases.
A new report by the Centers for Disease Control and Prevention is pushing states with high Medicaid smoking rates to do more to encourage enrollees to quit and live longer.
The Indianapolis-based company, which last month struck out in a late-stage clinical trial for a potential Alzheimer’s drug called solanezumab, announced Friday a collaboration with AstraZeneca to develop another possible treatment for the mind-robbing disease.
An Indiana state official in charge of regulatory oversight of nursing homes and residential care facilities has been barred from taking a job at a private company that runs senior living communities over ethics concerns.
U.S. health insurers signaled Tuesday that they’re willing to give up a cornerstone provision of Obamacare that requires all Americans to have insurance.
The FDA says the Indianapolis-based drugmaker and its partner can make an important label claim on its new diabetes drug—a move analysts say could give sales a big boost.
With drug companies under fire, the world’s largest insulin maker plans to limit price increases and introducing a model that ties the cost of medicines to the results they deliver.
Eli Lilly and Co. plans to lay off hundreds of U.S. sales representatives in coming months, following the disappointing failure of an experimental drug for Alzheimer’s disease announced last week.
Eli Lilly and Co. employees knew the Alzheimer's treatment solanezumab was not a sure bet. But that didn’t make the pain any less acute after the company announced the drug had failed to demonstrate effectiveness during a 2,100-patient Phase 3 clinical trial.
Twenty-three percent of Cigna’s domestic revenue would need to be rebranded to comply with rules of the Blue Cross Blue Shield association, said Anthem executive Steve Schlegel under questioning Wednesday by a Justice Department lawyer.
The rift between merging health insurance companies Cigna Corp. and Anthem Inc. came further into public view Tuesday as transcripts of testimony from both chief executives were unsealed during a U.S. antitrust trial
Anthem Inc. fired back against U.S. claims that the health insurer’s planned $48 billion takeover of rival Cigna Corp. will undermine competition.
The $6.3 billion bill would let the Food and Drug Administration approve drugs and medical devices more quickly and bolster federal mental health programs.
President-elect Donald Trump on Tuesday said he’ll nominate Seema Verma, founder of Indianapolis-based SVC Inc. and architect of the Healthy Indiana Plan, as his pick for administrator of the Centers for Medicare and Medicaid Services.
What happens to a laboratory glove after a doctor, nurse or lab worker snaps it off and throws it in the bin? Usually, it goes to a landfill, but Purdue and partners are working to change that.
Cornerstone Autism Center plans to hire about 30 employees in the next year in the 96-year-old Polk Building, which is undergoing a major rehab by its new owner.
